Uliledlimab
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer[1].
Product Specifications
CAS Number
2378407-27-1
Product Name Alternative
TJ004309
UNSPSC
12352203
Target
CD73
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/uliledlimab.html
Purity
99.35
Solubility
10 mM in DMSO
Smiles
[Uliledlimab]
Molecular Weight
(145.04 kDa)
References & Citations
[1]Fatima Z, et al., Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors. J Immunother Precis Oncol. 2023 Feb 2;6 (2) :91-102.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6442263-01 0.1 mL
UBE2D1 (Ubiquitin-conjugating Enzyme E2-D1, SFT, UBCH5, UBC4/5, UBCH5A, E2(17)KB1) (HRP)
Sign In for Pricing
View Details MBS6442263-02 5x 0.1 mL
UBE2D1 (Ubiquitin-conjugating Enzyme E2-D1, SFT, UBCH5, UBC4/5, UBCH5A, E2(17)KB1) (HRP)
Sign In for Pricing
View Details